Skip Navigation

Cardiovascular Research 2006 71(3):537-547; doi:10.1016/j.cardiores.2006.05.011
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Watanabe, K.
Right arrow Articles by Maruyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watanabe, K.
Right arrow Articles by Maruyama, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

Attenuated cardioprotection by ischemic preconditioning in coronary stenosed heart and its restoration by carvedilol

Kenichi Watanabe, Hiroyuki Yaoita, Kazuei Ogawa, Masayoshi Oikawa, Kazuhira Maehara and Yukio Maruyama*

First Department of Internal Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima 960-1295, Japan

* Corresponding author. Tel.: +81 24 547 1190; fax: +81 24 548 1821. Email address: maruyama{at}fmu.ac.jp

Objective: Infarct size (IS) reduction by ischemic preconditioning (IPC) has been assessed in the heart in which coronary stenosis (CS)-induced chronic ischemia was not present. The aim of this study is to assess whether and how IS reduction by IPC is modified in the heart in which CS has occurred, and how further therapeutics, if any, modify it.

Methods We assessed the IS produced by a 30-minute acute coronary occlusion and a 24-hour reperfusion (COR) in rat hearts in which CS had developed for 1–12 weeks. Modifications of IS by IPC and the mitochondrial KATP channel (mitoKATP) opener and blocker, and the effects of daily β-blocker treatment with carvedilol on them, were also assessed. Myocardial protein kinase C (PKC)-{varepsilon} activities in the risk areas were measured by Western blotting.

Results: One to 4 weeks after CS induction, myocardial PKC-{varepsilon} was activated in the risk area of CS even without IPC, but such CS-induced PKC activation as well as that by IPC was attenuated 8–12 weeks after CS. The IS reductions by the mitoKATP opener as well as by IPC were attenuated 8–12 and 4–12 weeks after CS, respectively. Daily carvedilol treatment after inducing CS restored the malfunctioning PKC-mitoKATP signal cascade and the attenuated IPC and mitoKATP effect on IS.

Conclusion CS activates the PKC-mitoKATP signal cascade, mimicking the IPC effect, whereas this cardioprotective effect is attenuated late after CS via their downregulation. Restoration of these changes may be a novel mechanism for cardioprotection by carvedilol in the CS-induced ischemic heart.

KEYWORDS Ischemia; Infarction; Preconditioning; Protein kinase C; Adrenergic antagonist; K-ATP channel

Time for primary review 28 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.